GLORIA

GEOMAR Library Ocean Research Information Access

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Herzschrittmachertherapie & Elektrophysiologie 10 (1999), S. 7-15 
    ISSN: 1435-1544
    Keywords: Schlüsselwörter Dilatative Kardiomyopathie ; dekompensierte ; Herzinsuffizienz ; permanentes Pacing ; Zweikammer-Pacing ; Schrittmacher-Hämodynamik ; Key words Dilated cardiomyopathy ; congestive heart failure ; permanent pacing ; biventricular pacing ; pacing hemodynamics
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Enthusiasm for permanent pacing as a therapeutic option for patients with dilated cardiomyopathy (DCM) and congestive heart failure (CHF) has waxed and waned since the early 1990‘s. The clinical results of standard dual-chamber pacing in these patients have been extraordinarily mixed, which can be attributed to small patient populations, marked heterogeneity of patients included, highly variable study designs and endpoints, and limited follow-up.  Although investigators have postulated some mechanisms for improvement, there is still a great deal to learn to be able to reliably predict which patients with DCM and/or CHF will respond to permanent pacing. Biventricular pacing is emerging as having the greatest potential for patients with congestive cardiomyopathy. Although data is somewhat limited, triple-chamber, and in some cases four-chamber pacing will be the focus of future interest.
    Notes: Zusammenfassung Die Begeisterung für das permanente Pacing als therapeutische Option bei der dilatativen Kardiomyopathie (DCM) und bei der dekompensierten Herzinsuffizienz (CHF) hat seit den frühen 90er Jahren deutlich nachgelassen. Die klinischen Ergebnisse des üblichen Zweikammer-Pacings fielen bei diesen Patienten außergewöhnlich gemischt aus. Dies kann auf kleine Patientenpopulationen, eine ausgeprägte Heterogenität der teilnehmenden Patienten, auf eine große Variabilität der Studiendesigns und Endpunkte sowie auf eine begrenzte Nachbeobachtungszeit zurückgeführt werden.  Obwohl Wissenschaftler einige Mechanismen für eine Besserung postulieren, sind viele Punkte noch offen, bis man zuverlässig voraussagen kann, welche Patienten mit DCM und/oder CHF auf ein permanentes Pacing ansprechen werden.  Es scheint so als ob das Zweikammer-Pacing das größte Potential für Patienten mit dekompensierter Herzinsuffizienz bietet. Obwohl erst limitierte Daten zur Verfügung stehen, wird in Zukunft das Dreikammer-Pacing und in manchen Fällen das Vierkammer-Pacing von Interesse sei.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Publication Date: 2014-08-15
    Description: High-throughput sequencing technologies, including RNA-seq, have made it possible to move beyond gene expression analysis to study transcriptional events including alternative splicing and gene fusions. Furthermore, recent studies in cancer have suggested the importance of identifying transcriptionally altered loci as biomarkers for improved prognosis and therapy. While many statistical methods have been proposed for identifying novel transcriptional events with RNA-seq, nearly all rely on contrasting known classes of samples, such as tumor and normal. Few tools exist for the unsupervised discovery of such events without class labels. In this paper, we present SigFuge for identifying genomic loci exhibiting differential transcription patterns across many RNA-seq samples. SigFuge combines clustering with hypothesis testing to identify genes exhibiting alternative splicing, or differences in isoform expression. We apply SigFuge to RNA-seq cohorts of 177 lung and 279 head and neck squamous cell carcinoma samples from the Cancer Genome Atlas, and identify several cases of differential isoform usage including CDKN2A , a tumor suppressor gene known to be inactivated in a majority of lung squamous cell tumors. By not restricting attention to known sample stratifications, SigFuge offers a novel approach to unsupervised screening of genetic loci across RNA-seq cohorts. SigFuge is available as an R package through Bioconductor.
    Keywords: Computational Methods
    Print ISSN: 0305-1048
    Electronic ISSN: 1362-4962
    Topics: Biology
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...